ESTRO 2025 - Abstract Book

S1411

Clinical - Lung

ESTRO 2025

Keywords: NSCLC, cardiac, overlap volume

References: [1] M. Polizzi, R. W. Watkins, and W. T. Watkins, “Data-Driven Dose-Volume Histogram Prediction,” Adv. Radiat. Oncol. , vol. 7, no. 2, Mar. 2022, doi: 10.1016/j.adro.2021.100841. [2] D. Mason, “SU ‐ E ‐ T ‐ 33: Pydicom: An Open Source DICOM Library,” Med. Phys. , 2011, doi: 10.1118/1.3611983. [3] A. Panchal and R. Keyes, “SU ‐ GG ‐ T ‐ 260: Dicompyler: An Open Source Radiation Therapy Research Platform with a Plugin Architecture,” in Medical Physics , 2010. doi: 10.1118/1.3468652.

3825

Digital Poster Stereotactic body radiation therapy versus surgery in early-stage Non-Small Cell Lung Cancer. Results in comorbid and no-comorbid population. Laura Martínez Ávila 1 , Sonia Mosteiro Molina 2 , Laura Pareja Fernández 2 , Míriam Núñez Fernández 1 , Susana Padrones Sánchez 3 , Yuanyuan Lin 1 , Margherita Moretti 1 , Marc Ruíz Domínguez 1 , Samantha Aso González 3 , Josefa Ribes Puig 2 , Arturo Navarro Martín 1 1 Oncología Radioterápica, Institut Català d’Oncologia - ICO L’Hospitalet, L’Hospitalet de Llobregat, Spain. 2 Registro de Tumores Hospitalarios Multicéntrico, Institut Català d’Oncologia - ICO L’Hospitalet, L'Hospitalet de Llobregat, Spain. 3 Neumología, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Spain Purpose/Objective: Surgery is the mainstay treatment for early-stage Non-Small Cell Lung Cancer (NSCLC). Stereotactic body radiation therapy (SBRT) has shown high local control with low treatment-related toxicity in patients not eligible for surgery. There is no consensus comparing effectiveness between two treatments.

This study compares overall survival (OS) of surgery versus SBRT in I-II stage NSCLC patients, considering comorbid conditions.

Material/Methods: Patients with clinical I-II stage NSCLC diagnosed between 2019-2021 were identified from Tumor Registry Database and classified by age, comorbidities and treatment (surgery vs SBRT). Comorbidity was evaluated using the Charlson Comorbidity Index (CCI) and split in three categories: no-comorbidity, low and high comorbidity.

A retrospective analysis was performed. Data analyzed include age, sex, histology, treatment, hospital admissions, follow-up and vital status. Kaplan-Meier and Hazard Ratio methods were performed.

Results: Overall 713 patients were identified and classified in two age groups: <75y (N=531) and ≥75y (N=182). Mean age was 68y (SD9.3) and 70.7% were male. The 40.5% of patients have no-comorbidity, 35.2% low and 24.3% high. All patients were diagnosed at early-stage (79.1% stage I, 20.1% stage II). Treatment distribution was 83.6% surgery and 16.4% SBRT. Median follow-up was 28 months (IQR18). One-year OS was 96.6% (95%CI 95.0-98.2) for surgery versus 93.5% (95%CI 87.6-99.9) for SBRT in <75y, and 92.1% (95%CI 87.6-96.9) versus 85.5% (95%CI 76.6-95.3) SBRT in ≥75y, respectively.

No-statistical differences in OS between surgery and SBRT were detected in no-comorbidity patients. In patients with low or high comorbidity by CCI, surgery showed better OS [see Table 1]. However, patients who underwent